Irsicaixa AIDS Research Institute - HIVACAT, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Cell Res. 2012 Dec;22(12):1637-9. doi: 10.1038/cr.2012.105. Epub 2012 Jul 10.
The potentially life-threatening adverse reactions to Abavacir (ABC), a nucleoside analog reverse transcriptase inhibitor for the treatment of HIV infection, have been known for several years to be limited to individuals expressing the HLA-B57:01 gene. Why the ABC hypersensitivity syndrome is only seen in HLA-B57:01-expressing subjects and what the precise mechanisms underlying this intolerance are remain however controversial. A series of recent studies, particularly a study by Illing et al. recently published in Nature, now answer some of these questions and offer new opportunities to better understand autoimmune disorders and prevent adverse reactions to other drugs.
阿巴卡韦（ABC）是一种用于治疗 HIV 感染的核苷类似物逆转录酶抑制剂，其可能危及生命的不良反应多年来一直仅限于表达 HLA-B57:01 基因的个体。然而，为什么 ABC 超敏反应综合征仅见于 HLA-B57:01 表达的受试者，以及这种不耐受的确切机制是什么，仍然存在争议。最近的一系列研究，特别是 Illing 等人最近在《自然》杂志上发表的研究，现在回答了其中的一些问题，并为更好地理解自身免疫性疾病和预防其他药物的不良反应提供了新的机会。
